[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed Inc. (RMD) director John Hernandez exercised stock options and sold the resulting shares on 08/18/2025. He executed option exercises totaling 2,575 shares at an exercise price of $148.90 per share and concurrently sold 2,575 shares at a weighted average sale price of $287.1026. Following these transactions his beneficial ownership decreased from 6,620 shares to 4,045. The filing notes options became exercisable on 11/11/2024 (with vesting rules) and that the sale price range was $286.90–$287.24.

Positive

• None.

Negative

• Director sold 2,575 shares, reducing beneficial ownership from 6,620 to 4,045 shares (a ~39% decline for this holder)
• Insider liquidity event occurred (exercise and sale same day), which some investors view negatively as decreased insider ownership

Insights

Financial Analyst

TL;DR: Routine option exercise and sale by a director, modest net reduction in ownership.

John Hernandez exercised 2,575 options at a strike of $148.90 and simultaneously sold 2,575 shares at a weighted average of $287.1026, realizing a material per-share gain versus strike price. The director's reported beneficial holding fell to 4,045 shares from 6,620, a decline of ~39%. This is a standard compensation-related liquidity action rather than an operational signal from the company. Impact on share count and potential dilution is immaterial at the company level given the small absolute share count relative to a large-cap issuer.

Corporate Governance Expert

TL;DR: Transaction appears consistent with option vesting and routine director liquidity; disclosure is timely and complete.

The Form 4 shows an exercise (code M) and an immediate sale (code S) executed the same day, with full disclosure of price range and weighted average sale price. Vesting terms cited (exercisable 11/11/2024 or at next annual meeting) explain timing. From a governance perspective, the filing meets Section 16 transparency requirements; the reduction in beneficial ownership is notable but not large enough alone to indicate governance issues.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hernandez John

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/18/2025		M		2,575	A	$148.9	6,620	D
ResMed Common Stock	08/18/2025		S		2,575	D	$287.1026(1)	4,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$148.9	08/18/2025		M			2,575	11/11/2024(2)	11/16/2030	ResMed Common Stock	2,575	$0	0	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $286.90 - $287.24. The price reported above reflects the weighted average sale price.

2. Represents the date options become exercisable. Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date.

	John Hernandez, Director	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did John Hernandez report on the Form 4 for RMD?

He exercised 2,575 options at an exercise price of $148.90 and sold 2,575 shares at a weighted average price of $287.1026 on 08/18/2025.

How did the transactions change John Hernandez's beneficial ownership of RMD?

Beneficial ownership decreased to 4,045 shares from 6,620 shares following the reported transactions.

What was the price range for the sale reported on the Form 4?

The sale trades occurred at prices ranging from $286.90 to $287.24, with a weighted average sale price of $287.1026.

When did the options become exercisable according to the filing?

The options became exercisable on 11/11/2024 (with vesting also possible at the first annual shareholders meeting following grant, per the filing).

Does the Form 4 indicate whether these transactions were part of a Rule 10b5-1 plan?

No—the Form 4 does not check or state that these transactions were made pursuant to a Rule 10b5-1 trading plan.